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Introduction: Chronic pancreatitis (CP) is an inﬂammatory disease characterized by
a progressive and irreversible loss of exocrine and endocrine pancreatic function. In
developed countries, an excessive consumption of alcohol explain the majority of the
CP cases, followed by “idiopathic” causes which account for about 20% of the cases.
In 1998, the CFTR gene has been suggested to play a role in idiopathic chronic
pancreatitis (ICP). Moreover, some CFTR mutations have been shown to selectively
disrupt bicarbonate conductance and therefore selectively target the pancreas for
CFTR-associated injury. In order to determine whether or not different types of
CFTR mutations affect the risk of developing CP, we recruited 244 patients with
ICP who have developed the disease before or at the age of 20 years.
Methods: The 27 exons and all the intron/exon junctions of the CFTR gene
were screened by denaturing high-performance liquid chromatography (DHPLC)
technique or by High-resolution melting analysis. The intron 8 poly (T) variants
were analyzed by using a ﬂuorescent multiplex PCR. Finally, quantitative ﬂuorescent
multiplex PCR (QFM-PCR) was performed to screen genomic rearrangements.
Results: About 30% of ICP patients are carrying at least one mutation of the CFTR
gene including the T5 allele in intron 8. This frequency appears about 10-fold higher
that the expected carrier rate in French population. Finally, it appears that about 10%
of ICP patients are compound heterozygotes (mild/mild or severe/mild mutations).
Conclusion: These data show that not only compound heterozygosity, but also CF
carrier status for different types of CFTR mutations, increase the risk of developing
CP. So, the idiopathic CP could be classiﬁed as so called CFTR related disease.
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Mutation in the CFTR gene is responsible of a large spectrum of clinical phenotype
from severe CF to male sterility due to congenital bilateral aplasia of the vas
deferens (CBAVD). More than 1500 CFTR mutations have already been described
and new semi quantitative approaches have been developed to evidence gross
rearrangements in the 27 exons of the gene. We have shown that these deletions
account for about 1 to 3% of the CF disease causing mutations worldwide. We
have described 8 new rearrangements and characterized their breakpoint junctions.
However this technique missed the intronic region as well as the 5′ and the 3′
UTR part of the gene. In this work, we designed an Agilent 15K custom array on
the locus CFTR to carefully analyse deletions or duplications. This oligonucleotide
array enable us to cover 2Mb encompassing the CFTR locus as well as the gene
itself. We tested 114 patients with CF in this study and evidenced the 11 deletions
collected in our laboratory from ﬁve countries worldwide. About the 109 DNA
samples for whom the genotype was incomplete, we observed 5 duplications and
2 deletions of several exons. We also screened 160 patients with CBAVD and 2
deletions were observed in intronic region. This analysis was useful to determine
accurately the 5′ and 3′ breakpoints of the variation. This allowed a rapid design of
primers to amplify the breakpoint junction and to obtain the sequence permitting the
characterisation of the defect at the molecular level. Our custom array is an excellent
tool allowing a rapid detection and a characterization of the rearrangements not only
the 27 exons of the gene but also those located throughout the 200 kb genomic
region of the CFTR gene.
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Scanning technique of the CFTR gene is usually required when the mutated alleles,
about 20%, are not identiﬁed by commercial genotyping assays. Distinct methods
such as D-HPLC or MLPA are routinely used to detect either point mutations or
large rearrangements. We report here a new one-step method for detecting both
types of gene modiﬁcations.
All 27 coding/ﬂanking regions of the CFTR gene and 2 reference genes were
ampliﬁed under identical ﬂuorescent conditions. Amplicons were then analysed
using the Lightcycler 480 (Roche) according to a closed-tube methodology not
requiring a post-PCR processing. Results of melting analysis (HRM) and relative
quantiﬁcation were compared with those of reference methods, DGGE/D-HPLC
and QMPSF/MLPA respectively.
A total of 344 different point variations, 11 various deletions or duplications
spanning 21 exons were successfully assessed in two separated laboratories. In
this series, the sensitivity of our method was 99.7% for heterozygous variants and
50% for homozygous variants. Thus, this one-step method is at least as efﬁcient as
the reference methods. Results were strongly reproducible, not operator dependant
and did not vary using DNA from different extraction methods (including DNA
from Guthrie cards). Moreover, PCR products were fully compatible for subsequent
restriction or sequencing analysis.
In conclusion, this combined HRM-real-time PCR method provides a robust, faster,
and low-cost alternative tool for complete CFTR scanning for diagnostic purpose
and can be easily transposable to other gene analysis.
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Twenty different CF mutations (CFTRdele2,3(21kb), 394delTT, 604insA,
L138ins, 621+1G>T, R334W, R347P, F508del, 1677delTA, G542X, 2143delT,
2184insA, K598ins, 3821delT, S1196X, 3677insTCAA, 3849+10kbC>T, W1282X,
3944delTG, N1303K) were accounted for 77% of CF alleles in Russian patients.
We have performed 123 prenatal diagnoses for 98 couples. Two cases included
twin pregnancies: one homozygous and one heterozygous. 74 families with 17
different genotypes were fully informative for direct DNA analysis performed by
using multiplexPCR, heteroduplex analysis and restriction analysis. In 19 families
only one parent mutant allele was known and in 5 families none of CF mutations
were identiﬁed, so prenatal analysis was done by indirect DNA analysis using
haplotype analysis of four dinucleotide repeats, one tetranucleotide repeat and four
biallelic restriction polymorphic sites. Materials used for fetal DNA analysis were
CVS samples. 30 fetuses were affected, 66 − heterozygous carriers and 28 were
healthy with two normal alleles of CFTR gene. In all cases when prenatal diagnosis
indicated that the fetus had CF the couples chose pregnancy termination.
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